Search Results - "Suda G"

Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.

Authors: Kawagishi, N. Suda, G. Onozawa, M. et al.

Source: Journal of Viral Hepatitis. Dec2017, Vol. 24 Issue 12, p1098-1106. 9p.

This result is not displayed to guests.
Login for full access.

P-171 Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet REFLECT trial inclusion criteria.

Authors: Sho, T. Suda, G. Ogawa, K. et al.

Source: Annals of Oncology. 2020 Supplement 3, Vol. 31, pS145-S146. 2p.

208P Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo+bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)–unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria

Authors: Yamashita, T. Ueshima, K. Tsuchiya, K. et al.

Source: Annals of Oncology. 2024 Supplement 4, Vol. 35, pS1483-S1484. 2p.

165P BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab.

Authors: Amadeo, E. Persano, M. Tada, T. et al.

Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1539-S1540. 2p.

967P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB).

Authors: Persano, M. Rimini, M. Tada, T. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS665-S665. 1p.

188P Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab.

Authors: Rimini, M. Amadeo, E. Vitiello, F. et al.

Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1548-S1548. 1p.

173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB).

Authors: Persano, M. Rimini, M. Tada, T. et al.

Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1543-S1543. 1p.

170P Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population.

Authors: Vitiello, F. Rimini, M. Persano, M. et al.

Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1541-S1541. 1p.

154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB).

Authors: Persano, M. Rimini, M. Tada, T. et al.

Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1535-S1535. 1p.

84P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population.

Authors: Rimini, M. Casadei-Gardini, A. Tada, T. et al.

Source: Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1466-S1466. 1p.

1035 HEAT SHOCK FACTOR 1 ACCELERATES HEPATOCELLULAR CARCINOMA DEVELOPMENT BY ACTIVATING NUCLEAR FACTOR κB/MITOGEN-ACTIVATED PROTEIN KINASE.

Authors: Chuma, M. Sakamoto, N. Hige, S. et al.

Source: Journal of Hepatology. Apr2013 Supplement 1, Vol. 58, pS425-S425. 1p.

661 COMPARISON OF HCV-ASSOCIATED GENE EXPRESSION AND CELL SIGNALING PATHWAYS IN CELLS WITH OR WITHOUT HCV REPLICON AND IN REPLICON-CURED CELLS

Authors: Nishimura-Sakurai, Y. Sakamoto, N. Mogushi, K. et al.

Source: Journal of Hepatology. Apr2010 Supplement 1, Vol. 52, pS258-S258. 1p.

Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.

Authors: Tanaka T Suda G Ohara M et al.

Source: Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2026 Jun; Vol. 17 (3), pp. e70305.

Publication Type: Journal Article

Journal Info: Publisher: John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders Country of Publication: Germany NLM ID: 101552883 Publication Model: Print Cited Medium: Internet ISSN: 2190-6009 (Electronic) Linking ISSN: 21905991 NLM ISO Abbreviation: J Cachexia Sarcopenia Muscle Subsets: MEDLINE

Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.

Authors: Tanaka T Suda G Ohara M et al.

Source: Frontiers in nutrition [Front Nutr] 2026 Feb 18; Vol. 13, pp. 1730695. Date of Electronic Publication: 2026 Feb 18 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Media S. A Country of Publication: Switzerland NLM ID: 101642264 Publication Model: eCollection Cited Medium: Print ISSN: 2296-861X (Print) Linking ISSN: 2296861X NLM ISO Abbreviation: Front Nutr Subsets: PubMed not MEDLINE

Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.

Authors: Yasuura N Suda G Ohara M et al.

Source: Journal of gastroenterology [J Gastroenterol] 2026 Jun 26. Date of Electronic Publication: 2026 Jun 26.

Publication Type: Journal Article

Journal Info: Publisher: Springer International Country of Publication: Japan NLM ID: 9430794 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-5922 (Electronic) Linking ISSN: 09441174 NLM ISO Abbreviation: J Gastroenterol Subsets: MEDLINE

HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapy.

Authors: Yokoyama D Suda G Ohara M et al.

Source: Virology journal [Virol J] 2026 Jun 19. Date of Electronic Publication: 2026 Jun 19.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1743-422X (Electronic) Linking ISSN: 1743422X NLM ISO Abbreviation: Virol J Subsets: MEDLINE

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Authors: Casadei-Gardini A Yip TC Vitale A et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2026 Jun 03; Vol. 240, pp. 116750. Date of Electronic Publication: 2026 Apr 21.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

Cachexia in Cirrhosis Is Characterized by Sex-Specific Loss of Muscle Mass and Adipose Tissue.

Authors: Miwa T Suda G Tateishi R et al.

Source: Hepatology research : the official journal of the Japan Society of Hepatology [Hepatol Res] 2026 May; Vol. 56 (5), pp. 873-874. Date of Electronic Publication: 2025 Dec 29.

Publication Type: Letter

Journal Info: Publisher: Blackwell Publishing Country of Publication: Netherlands NLM ID: 9711801 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1386-6346 (Print) Linking ISSN: 13866346 NLM ISO Abbreviation: Hepatol Res Subsets: PubMed not MEDLINE

Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.

Authors: Suda G Ohara M Baba M et al.

Source: The Journal of infection [J Infect] 2026 Apr; Vol. 92 (4), pp. 106715. Date of Electronic Publication: 2026 Feb 26.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE